Summary
EVLO Chart
Evelo Biosciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 5 | $0.02 | $0.02 | - | - |
| JM John Malone Amundi | 1,623.6 | $446.49 | $22.3 | -$424.19 | -95.01% |
Evelo Biosciences Inc. (EVLO) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Evelo Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Craig R. Jalbert CEO | NASDAQ (NGS) Exchange | 299734103 CUSIP |
| US Country | 66 Employees | - Last Dividend | 30 Jun 2023 Last Split | 9 May 2018 IPO Date |
Overview
Evelo Biosciences, Inc. is a pioneering clinical-stage biotechnology entity dedicated to the innovation and development of novel oral therapeutics. These emerging medications are designed to modulate immune cells located in the small intestine, consequently exerting systemic health effects. Since its establishment in 2014, Evelo has positioned itself at the forefront of leveraging microbial-based treatments for a range of systemic inflammatory conditions. The company is headquartered in Cambridge, Massachusetts, reflecting its roots in one of the world's leading biotechnology hubs.
Products and Services
EDP1815 - This whole-microbe product candidate has recently completed a Phase 2 clinical trial aimed at treating psoriasis. Additionally, EDP1815 is currently undergoing another Phase 2 trial, this time targeting atopic dermatitis. This moves Evelo closer to potentially offering new therapeutic options for patients suffering from these challenging skin conditions.
EDP1867 - Evelo is developing this non-live pharmaceutical preparation of a single strain of Veillonella parvula. Currently, EDP1867 is in a Phase 1b clinical trial phase. This product candidate underscores Evelo's innovative approach to targeting specific microbial strains for therapeutic purposes.
EDP2939 - As an investigational oral biologic, EDP2939 represents Evelo's commitment to expanding its portfolio towards treating inflammatory diseases. Although still in the early stages of development, EDP2939 holds potential as a novel treatment option for inflammatory conditions, illustrating the broad applicability of Evelo's microbial-based therapeutic strategy.
EDP1908 - This product candidate is another testament to Evelo's versatile research approach, targeting oncology. With EDP1908, Evelo is exploring the potential of microbial-based treatments to combat cancer, opening new avenues in the field of oncology therapeutics.
